أعرض في EDS

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma

التفاصيل البيبلوغرافية
العنوان: Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma
المؤلفون: Roberta Marciano, Bianca Maria Veneziani, Roberta De Rosa, Vincenzo Damiano, Roberto Bianco, Sabino De Placido, Luigi Formisano, Lucia Nappi
المساهمون: Rosa, R., Damiano, V., Formisano, L., Nappi, L., Marciano, R., Veneziani, BIANCA MARIA, DE PLACIDO, Sabino, Bianco, Roberto
المصدر: Oncoimmunology
بيانات النشر: Informa UK Limited, 2013.
سنة النشر: 2013
مصطلحات موضوعية: Agonist, renal cell carcinoma, medicine.drug_class, Immunology, Pharmacology, urologic and male genital diseases, TLR9, Renal cell carcinoma, medicine, Immunology and Allergy, Receptor, Author's View, PI3K/AKT/mTOR pathway, Everolimus, business.industry, everolimu, everolimus, medicine.disease, microenvironment, female genital diseases and pregnancy complications, Toll-Like Receptor 9, Clinical trial, Oncology, mTOR, business, medicine.drug
الوصف: The mTOR inhibitor everolimus is currently approved for the treatment of renal cell carcinoma (RCC) and several Toll-like receptor 9 (TLR9) agonists, including immunomodulatory oligonucleotides (IMOs), have been tested for their therapeutic potential against advanced RCC. However, no clinical trials investigating the combination of mTOR inhibitors with TLR9 agonists in RCC patients have been performed to date. Our results may pave the way to translate this combinatorial approach to the clinical setting.
تدمد: 2162-402X
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fc907f3406adfc4ae63d2f00f03769eTest
https://doi.org/10.4161/onci.25123Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....7fc907f3406adfc4ae63d2f00f03769e
قاعدة البيانات: OpenAIRE
الوصف
تدمد:2162402X